Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
about
Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral painAdvances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideLinaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adultsCurrent developments in pharmacological therapeutics for chronic constipationFrom Escherichia coli heat-stable enterotoxin to mammalian endogenous guanylin hormonesTreatment for constipation: new and old pharmacological strategiesGuanylyl cyclase C signaling axis and colon cancer preventionResponders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-CPotential strategies for increasing drug-discovery productivity.Sildenafil normalizes bowel transit in preclinical models of constipationA Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic ConstipationLinaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationLuminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.The uroguanylin system and human disease.Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.Review article: Linaclotide for the management of irritable bowel syndrome with constipationComparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C.Optimal management of constipation associated with irritable bowel syndromeLinaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialChronic constipation: new diagnostic and treatment approachesLinaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation.Predicting liver metastasis of gastrointestinal tract cancer by diffusion-weighted imaging of apparent diffusion coefficient valuesLinaclotide (Linzess) for Irritable Bowel syndrome With Constipation and For Chronic Idiopathic ConstipationCFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipationManagement Strategies for Abdominal Bloating and Distension.Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.Linaclotide.Novel pharmacological therapies for management of chronic constipation.Role of Quercetin in Modulating Chloride Transport in the Intestine.Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.Linaclotide: a novel approach to the treatment of irritable bowel syndrome.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
P2860
Q26863234-140A0B83-ABC4-4721-96F2-5FFFA396B559Q26865304-17FBA678-F9CF-4398-AB22-51CA23D3E2BDQ27010449-5E245B51-838E-476A-9BC0-DA6F397106E2Q27025474-94AED9B3-0D4B-403E-9A42-E75D5240A6A3Q27025808-C102FF3F-22C5-44AA-B8D2-1629D5C15468Q27027346-1B0E5FD0-F704-44A9-8375-2555CE23D4B3Q28074181-B24DAC25-4B45-4359-B4E7-8A5A7B02E9F7Q30724990-6AC14B38-CD68-4E40-B7B5-047E9E534419Q31154360-F226B95F-8FBB-4066-BDDB-5E76C8F85241Q33610799-86BCBEBD-C424-4F00-AFAA-498B934C6F69Q33634439-6FF84642-55C9-49CA-B846-23A18CF36DB0Q33695487-B2F5FCA0-2F45-442D-9887-FD43B741EA1FQ33854983-0BC754A3-6816-4E04-9F5E-3AFC591B276CQ33855973-313CEA27-31ED-47E0-B512-A339F976763BQ33958710-676210EC-C772-4BC8-89AE-AB052821EE2BQ34254749-A72C913F-C911-4F9A-8347-2ABC1F283D92Q34293073-1378257F-3332-455F-AB2A-95EB7537E95FQ34309302-9A05588C-EE05-4EBC-BFC0-C43316C00FB3Q34522966-F152AEAA-46BE-4A8E-86BF-CA28F81123E5Q34709012-B54BAC3B-F684-4C76-B833-29257E64701AQ35008626-37BE89DE-4886-44A2-A400-941E299FC140Q35044200-EF87A26D-451D-444A-9AFC-70FF60A20B44Q35586543-E134ABBE-88AA-47B7-AA43-B1F5102C0A36Q35723125-DF10364E-8F21-4757-A44B-ACE8A75892BFQ36072686-27D39FF9-9273-4FD9-91B7-C1DD237B3B2DQ36092886-BF3C13B2-9DFA-4431-B134-3986253020F6Q36656627-15DC4E5B-628F-465B-BA2B-D828143D409AQ36801233-2FD1CC9B-E17B-4620-8685-845ECACA38EBQ36833766-7329F463-E115-445B-9882-31327D430FDEQ37190545-56A8C080-EBE4-4178-9D7D-14DC59FF5239Q37253910-7F35B6E2-7772-4A4F-B7DB-A06AED8D2627Q37340041-B8CD968A-A81F-435F-A3FD-EEF137F44749Q37394824-253B5762-2D90-40CB-9F90-F82039669E92Q37430357-C8AF9576-0C29-40A8-AE56-3624F9E7BC2DQ37671189-EB2A7EE7-952D-41DF-B5F6-7D84811F9723Q37699695-3A7E46DD-4E68-44E4-8482-574E3369E88DQ37859025-EEC39DA0-7176-4F7D-A117-9422EDECAA4BQ37886156-4185FA3F-DFB2-451D-90FF-944012F0D6E7Q37951907-B6341B8D-CB99-463A-97F8-39D6C3301E72Q37954521-A8D841F6-10FF-476C-A646-A46592720EBB
P2860
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Linaclotide, through activatio ...... estinal secretion and transit.
@en
Linaclotide, through activatio ...... estinal secretion and transit.
@nl
type
label
Linaclotide, through activatio ...... estinal secretion and transit.
@en
Linaclotide, through activatio ...... estinal secretion and transit.
@nl
prefLabel
Linaclotide, through activatio ...... estinal secretion and transit.
@en
Linaclotide, through activatio ...... estinal secretion and transit.
@nl
P2093
P1476
Linaclotide, through activatio ...... estinal secretion and transit.
@en
P2093
Alexander P Bryant
Caroline B Kurtz
Christine M Pierce
Etchell A Cordero
Gerhard Hannig
Jenny V Tobin
Li Jing Sun
Marco M Kessler
Mark G Currie
Robert M Solinga
P304
P356
10.1016/J.EJPHAR.2010.09.019
P407
P577
2010-09-20T00:00:00Z